Non-small-cell lung carcinoma

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Retrieved on: 
Monday, November 22, 2021

Non-small cell lung cancer impacts nearly 200,000 patients every year in the U.S., and lung cancer is the leading cause of cancer-related death globally.

Key Points: 
  • Non-small cell lung cancer impacts nearly 200,000 patients every year in the U.S., and lung cancer is the leading cause of cancer-related death globally.
  • LUNAR will provide the first randomized dataset to evaluate increased survival when Tumor Treating Fields is used together with immunotherapy, versus immunotherapy alone.
  • Lung cancer is the most common cause of cancer-related death worldwide, and NSCLC accounts for approximately 85% of all lung cancers.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Retrieved on: 
Monday, November 15, 2021

We are extremely pleased to share promising clinical data showing safety and superior efficacy of our SNK01 autologous NK cell therapy in combination with pembrolizumab, said Sangwoo Park, Chief Executive Officer of NKGen Biotech.

Key Points: 
  • We are extremely pleased to share promising clinical data showing safety and superior efficacy of our SNK01 autologous NK cell therapy in combination with pembrolizumab, said Sangwoo Park, Chief Executive Officer of NKGen Biotech.
  • The results of the trial demonstrate that SNK01 can be safely combined with checkpoint inhibitors, resulting in meaningfully improved clinical outcomes, especially compared to the checkpoint inhibitor alone.
  • We look forward to seeing similar results in other solid tumor settings as we continue the clinical development of SNK01.
  • In this trial, combination of SNK01 and pembrolizumab enhanced antitumor activity in advanced NSCLC patients, and suggests possible utilization of combining SNK01 with pembrolizumab.

Genetron Health Wins Second Prize of China’s National Science and Technology Progress Award for Contributions to Lung Cancer Precision Medicine Project

Retrieved on: 
Wednesday, November 3, 2021

Genetron Health stood out as the only award recipient that focused on precision oncology this year.

Key Points: 
  • Genetron Health stood out as the only award recipient that focused on precision oncology this year.
  • The National Science and Technological Progress Award is one of the five National Science and Technology Awards, established by the State Council in China.
  • Led by Professor Li Weimin from West China Hospital Sichuan University, the initiative received significant support from Genetron Health.
  • The project focused on tackling the issue of missed diagnosis in early-stage lung cancer and built a forecasting model based on imaging.

OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®

Retrieved on: 
Monday, October 11, 2021

This new patent notice of allowance granted in Europe reinforces the patent protection for Tedopi and confirms an optimized industrial manufacturing process using a ready-to-use peptide emulsion.

Key Points: 
  • This new patent notice of allowance granted in Europe reinforces the patent protection for Tedopi and confirms an optimized industrial manufacturing process using a ready-to-use peptide emulsion.
  • Tedopi has shown positive final results from the Atalante 1 Phase 3 study in non-small cell lung patients after secondary resistance to immune checkpoint inhibitors (presented at the 2021 ESMO (European Society for Medical Oncology) Congress ).
  • Such combinations will further reinforce the therapeutic value of Tedopi in late-stage cancer indications.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Oncology Is a Major Focus for Many AI Drug Discovery Companies, Reports IDTechEx

Retrieved on: 
Thursday, October 7, 2021

In this article, IDTechEx reports on the analysis of 25 AI drug discovery companies (out of 100 total companies identified) that are actively developing drug candidates and have published detailed information on their drug development pipeline.

Key Points: 
  • In this article, IDTechEx reports on the analysis of 25 AI drug discovery companies (out of 100 total companies identified) that are actively developing drug candidates and have published detailed information on their drug development pipeline.
  • Within the AI drug discovery landscape, several companies, such as Erasca, Relay Therapeutics, and Turbine AI, focus entirely on the development of cancer therapies.
  • Beyond oncology, IDTechEx found the landscape fragmented, with neurology (including neurodegenerative diseases) and inflammatory diseases to be of particular focus by AI drug discovery companies.
  • For the most part, IDTechEx found that AI drug discovery companies are still in the early stages of drug development.

Oncology Is a Major Focus for Many AI Drug Discovery Companies, Reports IDTechEx

Retrieved on: 
Thursday, October 7, 2021

In this article, IDTechEx reports on the analysis of 25 AI drug discovery companies (out of 100 total companies identified) that are actively developing drug candidates and have published detailed information on their drug development pipeline.

Key Points: 
  • In this article, IDTechEx reports on the analysis of 25 AI drug discovery companies (out of 100 total companies identified) that are actively developing drug candidates and have published detailed information on their drug development pipeline.
  • Within the AI drug discovery landscape, several companies, such as Erasca, Relay Therapeutics, and Turbine AI, focus entirely on the development of cancer therapies.
  • Beyond oncology, IDTechEx found the landscape fragmented, with neurology (including neurodegenerative diseases) and inflammatory diseases to be of particular focus by AI drug discovery companies.
  • For the most part, IDTechEx found that AI drug discovery companies are still in the early stages of drug development.

Global Clinical Oncology Next Generation Sequencing Market Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 4, 2021

The "Global Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report by Workflow, by Technology (WGS, WES), by Application (Screening, Companion Diagnostics), by End-use, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report by Workflow, by Technology (WGS, WES), by Application (Screening, Companion Diagnostics), by End-use, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • Technological advancements in next-generation sequencing coupled with high adoption of companion diagnostics and personalized medicine drive the global market growth.
  • In addition, a rise in the utility of next generation sequencing (NGS) for liquid biopsy is expected to increase revenue generation in the market.
  • Moreover, a rise in market competitiveness, growth in oncology diagnostics spending, and increasing research activities to develop solutions that can potentially be used for clinical oncology drive market progression.

Study Finds the Combination of Optical Genome Mapping and Short-Read Sequencing Provides a Comprehensive Genome Analysis for Lung Cancer Samples and Enables the Discovery of New Biomarkers

Retrieved on: 
Thursday, September 16, 2021

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study finding the combination of optical genome mapping (OGM) and short-read next-generation sequencing (NGS) provides a comprehensive genome analysis for lung cancer samples and enables the discovery of new biomarkers.

Key Points: 
  • SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study finding the combination of optical genome mapping (OGM) and short-read next-generation sequencing (NGS) provides a comprehensive genome analysis for lung cancer samples and enables the discovery of new biomarkers.
  • In this study, recurrently SV-disrupted genes were significantly enriched in cancer-related pathways highlighting the importance of OGM for detecting all classes of SVs.
  • This study utilized short-read NGS and Bionanos OGM to obtain high-technical-confidence somatic SVs to investigate candidate oncogenes in cancer patients.
  • An essential role of high-technical-confidence somatic SVs guided the identification of two new oncogenes (TRIO and SESTD1) in NSCLC.

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress

Retrieved on: 
Thursday, September 16, 2021

The dataset is being presented in a poster titled MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion (Poster #620P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.

Key Points: 
  • The dataset is being presented in a poster titled MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion (Poster #620P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.
  • As of the August 16, 2021 data cut-off, all 40 patients in the mCRPC cohort expansion had been enrolled.
  • As of the August 16, 2021 data cut-off, the NSCLC cohort expansion had been fully enrolled with 21 patients.
  • The safety analysis includes all 86 patients enrolled in the cohort expansion as of the August 16, 2021 data cut-off.

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

Retrieved on: 
Wednesday, September 8, 2021

HEIDELBERG, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended June 30, 2021, and provided an update on clinical and corporate progress.

Key Points: 
  • HEIDELBERG, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended June 30, 2021, and provided an update on clinical and corporate progress.
  • We are pleased with the continued progress in our development of AFM13, AFM24 and AFM28, said Adi Hoess, CEO of Affimed.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.
  • Affimed will host a conference call and webcast today, September 8, 2021, at 8:30 a.m. EDT to discuss second quarter 2021 financial results and recent corporate developments.